Our Focus

 Life-threatening, invasive fungal infections cause over 3.75 million deaths worldwide and are a growing public health concern, particularly in immunocompromised individuals.  There are currently no fungal vaccines approved for clinical use and no broad strategy for prevention of invasive fungal infections in high-risk populations

NXT Biologics is addressing this problem by developing a First-in-Class anti-fungal vaccine and monoclonal antibodies that prevent and treat infections due to multiple fungal pathogens.  

Learn More About Our Science